An Ex-US Study to Assess Treatment Persistence With Risankizumab in Adult Participants With Psoriatic Arthritis
This study is for people living with psoriatic arthritis, a condition where your immune system mistakenly attacks your joints, often alongside a skin condition called psoriasis. Doctors want to understand how a medicine called risankizumab works over a long time when compared to other treatments for psoriatic arthritis. This helps them see how effective it is in everyday medical care. The study will involve around 900 to 1200 people from various countries outside the United States. Participants will receive their medication as usual and have their check-ups during routine doctor visits for two years. The study aims to gather important real-world information without adding extra burdens for those taking part.
A colpo d'occhio
Di cosa tratta questo studio?
You might be interested in this study if you have psoriatic arthritis. This condition is a type of joint pain and stiffness, which often occurs in people who also have the skin condition psoriasis. It happens because your body's defence system, called the immune system, mistakenly attacks healthy parts of your body.
This study wants to learn more about how a medicine called risankizumab (pronounced riz-AN-ki-zoo-mab) helps people with psoriatic arthritis over a long period. They will compare it with other advanced medicines that doctors usually prescribe for this condition. The aim is to understand how well risankizumab works and how it's used in normal medical practice, rather than in strict experimental conditions.
Risankizumab is already approved for treating psoriatic arthritis. This study will take place in about 15 countries outside the U.S. and involve at least 900 to 1200 participants. Most participants will receive risankizumab, while others will receive different advanced treatments. Your treatment will be given in the usual way, just as your doctor would normally prescribe it, following current medical guidelines.
Punti chiave
- This study evaluates risankizumab for psoriatic arthritis.
- It aims to understand long-term effectiveness in real-world settings.
- Participants will follow their usual medical treatment and appointments.
- The study lasts for 24 months, with no extra patient burden.
- It's open to adults aged 18-75 with inadequately controlled psoriatic arthritis.
Chi può essere idoneo?
To be considered for this study, you would need to have been diagnosed with psoriatic arthritis for at least six months and have active symptoms of the condition at the start of the study. You also need to be between 18 and 75 years old.
Another important requirement is that your current psoriatic arthritis treatment, which might include certain medicines called DMARDs (Disease-modifying antirheumatic drugs), hasn't worked well enough for you. Alternatively, you might be eligible if you can't take certain standard DMARDs because of side effects or other medical reasons, as judged by your doctor.
However, you would not be able to join the study if three or more advanced biological or targeted synthetic DMARD medicines have not worked for you in the past.
Questo studio potrebbe fare al caso tuo?
Rispondi a queste domande rapide per vedere se potresti essere idoneo. Questo è solo una guida — il team di ricerca prende la decisione finale.
- Do you have a diagnosis of psoriatic arthritis?
- Have you had psoriatic arthritis symptoms for at least 6 months?
- Hai tra i 18 e i 75 anni?
- Has your current psoriatic arthritis treatment not worked well enough, or can you not take certain standard medications?
- Have you not previously tried and failed three or more advanced biologic or targeted synthetic medications for psoriatic arthritis?
Cosa comporta la partecipazione?
If you join this study, you will receive your prescribed medication (either risankizumab or another advanced treatment) in the way your doctor usually gives it, following standard medical guidelines. You will attend your regular doctor's appointments and check-ups for your psoriatic arthritis. These visits will be counted as part of the study information gathering. There won't be any extra appointments or tests beyond what you would normally have.
The study will follow you for a total of two years (24 months). During this time, the researchers will collect information from your routine visits about how your treatment is working and how you are getting on. The idea is that taking part should not add any extra burden to your usual medical care.
Rischi e benefici potenziali
Locations (132)
- Cer Instituto Médico /ID# 274445Codice postale verificatoQuilmes, Argentina· Reclutamento
- Instituto Medico de Alta Complejidad San Isidro S.A. /ID# 274417Codice postale verificatoSan Isidro, Argentina· Reclutamento
- Instituto Médico Río Cuarto /ID# 274421Codice postale verificatoRío Cuarto, Argentina· Reclutamento
- Landesklinikum Stockerau /ID# 275618Codice postale verificatoStockerau, Austria· Reclutamento
- Rheuma-Zentrum Wien-Oberlaa GmbH /ID# 275617Codice postale verificatoVienna, Austria· Reclutamento
- Medizinische Universitaet Graz /ID# 273765Codice postale verificatoGraz, Austria· Reclutamento
- Krankenhaus Der Barmherzigen Brueder Graz /ID# 273764Codice postale verificatoGraz, Austria· Reclutamento
- Universite Libre de Bruxelles - Hopital Erasme /ID# 272763Codice postale verificatoAnderlecht, Belgium· Reclutamento
- Rhumaconsult Sprl /ID# 272797Codice postale verificatoCharleroi, Belgio· Reclutamento
- Reumacentrum Genk - Medisch Centrum Genk /ID# 272796Codice postale verificatoGenk, Belgio· Reclutamento
- ReumaClinic /ID# 272782Codice postale verificatoGenk, Belgio· Reclutamento
- OLV Ziekenhuis Aalst /ID# 274456Codice postale verificatoAalst, Belgium· Reclutamento
Domande comuni
Che cos'è l'artrite psoriasica?
Psoriatic arthritis is a type of arthritis that causes joint pain, swelling, and stiffness in people who often have the skin condition psoriasis. It happens when the body's immune system attacks healthy tissues by mistake.
What is risankizumab?
Risankizumab is a medicine that has been approved to treat psoriatic arthritis. This study wants to see how well it works over time in everyday use.
Will I have extra doctor appointments if I join?
No, you shouldn't have any extra appointments. All the study visits will happen during your normal, routine check-ups for your psoriatic arthritis.
How long will the study last if I take part?
If you join, you will be followed for two years (24 months) to observe how your treatment is working.
Will taking part in this study cost me anything?
The study aims to observe treatment in usual care, so there should be no additional costs or burdens for participants beyond your normal medical care.
Come saperne di più
Shari Chapman
Parla sempre con il tuo medico di base o specialista prima di decidere di partecipare a uno studio.
Interessato a partecipare?
Discussione
Discussione della comunità
Supportato dal nostro forum su community.patient.info. Si prega di essere rispettosi — questo non è un consiglio medico.